Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | Current and upcoming CAR-T’s for large B-cell lymphoma

Frederick Locke • 2 Jun 2019
ASCO 2019
B-Cell Lymphoma Lymphoma Axicabtagene ciloleucel Tisagenlecleucel
JULIET TRANSCEND-NHL-001 ZUMA-1

Frederick Locke, MD, of the Moffitt Cancer Center, Tampa, FL, discusses the CAR T-cell therapies available for the treatment of large B-cell lymphoma, and also what is to come for CAR-T treatments for this indication. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Frederick Locke

15:38
Highlights from Day 3: pushing the boundaries of CAR-T therapy in multiple myeloma & lymphoma
Frederick Locke et al. • 1 May 2022
3:52
Impact of age and co-morbidities on axi-cel efficacy
Frederick Locke • 29 Nov 2021
6:37
ZUMA-7: Axi-cel in r/r large B-cell lymphoma
Frederick Locke • 29 Nov 2021
1:15
The benefits of second-line CAR-T cell therapy
Frederick Locke • 29 Nov 2021

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals